United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - vinorelbine tartrate - solution for infusion - 10mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 20.00 mg

Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 30.00 mg

Namibia - English - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - vinorelbine tartrate - injection - each 1 ml vial contains; vinorelbine tartrate equivalent to vinorelbine 10,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - vinorelbine tartrate -

Israel - English - Ministry of Health

perrigo israel agencies ltd - vinorelbine as tartrate - concentrate for solution for infusion - vinorelbine as tartrate 10 mg/ml - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer. hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or estramustin.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.